文献速递其他结缔组织病

曲前列尼尔治疗系统性硬化症钙质沉着的安全性与有效性初步研究

A pilot study to evaluate the safety and efficacy of treprostinil in the treatment of calcinosis in systemic sclerosis.
PubMed 文献 · Rheumatology (Oxford) · 2022-01-01

这项前瞻性开放标签研究纳入12例符合2013年ACR/EULAR分类标准且有手部钙质沉着临床和影像学证据的系统性硬化症(SSc)患者,口服曲前列尼尔治疗1年。5例完成研究,7例因不耐受不良事件等原因退出;完成者中4例(80%)钙质沉着稳定,但口服曲前列尼尔耐受性差。

要点

  • 口服曲前列尼尔在SSc钙质沉着患者中耐受性差,多数出现头痛和胃肠道不良事件。
  • 完成治疗的5例中4例(80%)手部X线钙质沉着稳定,1例进展。
  • 有1年随访手部X线片的11例中4例(36%)出现钙质沉着进展。

核心结论

  • 口服曲前列尼尔在SSc钙质沉着患者中耐受性差,完成治疗的5例中多数(80%)1年时手部X线钙质沉着稳定。

研究设计与样本

  • 前瞻性开放标签研究纳入12例符合2013年ACR/EULAR分类标准且有手部钙质沉着临床和影像学证据的SSc患者,口服曲前列尼尔治疗1年。

主要发现

  • 12例女性患者入组,半数弥漫性皮肤病变,中位年龄55岁(范围35-68岁)。
  • 5例完成研究,7例退出:不耐受不良事件3例、并发无关疾病2例(肝硬化、癌症)、SSc进展1例、个人原因1例。
  • 多数患者出现头痛和胃肠道不良事件。
  • 有1年随访手部X线片的11例中4例(36%)钙质沉着进展。
  • 完成治疗的5例中钙质沉着稳定4例(80%),进展1例。

关键数值与推荐

  • 主要终点为安全性和耐受性以及1年时无影像学钙质沉着进展的患者百分比(硬皮病临床试验联盟影像学评分增加<25%)。
  • 次要终点包括硬皮病HAQ(SHAQ)、Cochin手功能量表、医学结局调查简表36(SF-36)、雷诺现象状况评分以及患者/医生对钙质沉着严重程度的评估的1年变化。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: We evaluated the safety and efficacy of oral treprostinil in preventing progression of SSc-associated calcinosis. METHODS: This prospective open-label study enrolled 12 SSc patients meeting 2013 ACR/EULAR classification criteria with confirmed clinical and radiographic evidence of one or more calcinosis deposit in the hands. Patients received oral treprostinil for 1 year. Primary endpoints were safety/tolerability and percentage of patients without radiographic progression of calcinosis at 1 year (<25% increase in Scleroderma Clinical Trials Consortium radiographic score). Secondary endpoints included 1-year changes in Scleroderma HAQ (SHAQ), Cochin Hand Functional Scale, Medical Outcomes Survey Short Form 36 (SF-36), Raynaud Condition Score and patient/physician assessment of calcinosis severity. RESULTS: Twelve female patients were enrolled, half with diffuse cutaneous disease; median age was 55 years (range 35-68 years). Five patients completed the study. Seven patients withdrew due to intolerable adverse effects (n = 3), intercurrent unrelated illness (n = 2, cirrhosis, cancer), progressive SSc (n = 1) and personal reasons (n = 1). Most patients developed headaches and gastrointestinal adverse effects. Four of 11 (36%) patients with 1-year follow-up hand radiographs experienced progression of calcinosis. Of five who completed treatment, calcinosis was stable in four (80%) with progression in one. Based on SF-36 Physical and Mental Component and Domain scores, transition question and SF-6D utility score, all patients who finished the trial reported overall improvement or no change compared with baseline. CONCLUSION: Oral treprostinil was poorly tolerated in SSc patients with calcinosis. Of five patients who completed treatment, most (80%) had documented stability of calcinosis on hand radiographs at 1 year. CLINICALTRIALS.GOV IDENTIFIER: NCT02663895.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Chung MP, Valenzuela A, Li S, et al. A pilot study to evaluate the safety and efficacy of treprostinil in the treatment of calcinosis in systemic sclerosis. Rheumatology (Oxford). 2022. PMID: 34718447. doi:10.1093/rheumatology/keab810

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。